Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04102020 · ClinicalTrials.gov registry record · Phase 3

A Study of Oral Venetoclax Tablets and Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy

A Phase 3 study of Acute Myeloid Leukemia (AML), sponsored by AbbVie.

Active
Registry status
Phase 3
Development phase
112
Enrollment target
20
Study locations

NCT04102020 is a Phase 3 study of Acute Myeloid Leukemia (AML) that is active but no longer recruiting, run by AbbVie. The registered enrollment target is 112 participants, below the 142-participant average among 29 other Acute Myeloid Leukemia (AML) trials with a reported enrollment target (21% lower). The trial reports 20 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04102020, a Phase 3 study of Acute Myeloid Leukemia (AML), is active but no longer recruiting, sponsored by AbbVie.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
112 participants
Enrollment target
20
Study locations

Study Summary

This study will be conducted in two parts. Part 1 will be the Dose Confirmation portion to determine recommended Phase 3 dose (RPTD) of venetoclax in combination with azacitidine (AZA). Part 3 will be the Dose Finding portion to determine RPTD of venetoclax in combination with AZA. Part 2 and Part 3 Randomization of the study were removed.

Conditions Studied

Acute Myeloid Leukemia (AML)

Interventions

  • DRUG Venetoclax
  • DRUG Azacitidine

Study Locations (20)

Massachusetts

  • Tufts Medical Center /ID# 216110 - Boston
  • Massachusetts General Hospital /ID# 217307 - Boston
  • Duplicate_UMass Chan Medical School /ID# 218163 - Worcester

California

  • Compassionate Cancer Care Research Group - Fountain Valley /ID# 216156 - Fountain Valley
  • University of California, Los Angeles /ID# 219149 - Los Angeles

Kentucky

  • University of Kentucky Markey Cancer Center /ID# 215048 - Lexington
  • Duplicate_Norton Cancer Institute /ID# 216401 - Louisville

Louisiana

  • Tulane Medical Center - New Orleans /ID# 218166 - New Orleans
  • Duplicate_Ochsner Clinic Foundation-New Orleans /ID# 214583 - New Orleans

Missouri

  • Oncology Hematology Associates (OHA) - Springfield /ID# 216351 - Springfield
  • Saint Louis University Cancer Center /ID# 218164 - St Louis

New Jersey

  • The John Theurer Cancer /ID# 215191 - Hackensack
  • Rutgers Cancer Institute of New Jersey /ID# 239708 - New Brunswick

Alabama

  • Mitchell Cancer Institute /ID# 216443 - Mobile

Colorado

  • Colorado Blood Cancer Institute /ID# 214280 - Denver

Trial Details

FieldValue
Enrollment Target 112 participants
Start Date 2020-03-26
Est. Completion 2026-06
Phase Phase 3

Sponsor

AbbVie

526 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04102020

The ClinicalTrials.gov registry entry for NCT04102020 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 112 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 142-participant average among 29 other Acute Myeloid Leukemia (AML) trials with a reported enrollment target (21% lower). The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Acute Myeloid Leukemia (AML) appearing as the primary indexed condition, and to 2 interventions - of which Venetoclax is the first listed.

NCT04102020 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Massachusetts, California, Kentucky.

Frequently Asked Questions

What is clinical trial NCT04102020 about?

NCT04102020 is a clinical study titled "A Study of Oral Venetoclax Tablets and Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy". This study will be conducted in two parts. Part 1 will be the Dose Confirmation portion to determine recommended Phase 3 dose (RPTD) of venetoclax in combination with azacitidine (AZA). Part 3 will be the Dose Finding portion to determine RPTD of venetoclax in combination with AZA. Part 2 and Part 3...

What is the current status of trial NCT04102020?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 112 participants. The study started on 2020-03-26. Estimated completion is 2026-06.

What conditions does trial NCT04102020 study?

This clinical trial studies the following conditions: Acute Myeloid Leukemia (AML).

What interventions are being tested in trial NCT04102020?

The interventions under investigation include: Venetoclax (DRUG), Azacitidine (DRUG).

Who is sponsoring clinical trial NCT04102020?

This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04102020 being conducted?

This trial has 20 study locations across Alabama, California, Colorado, Idaho, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Acute Myeloid Leukemia (AML)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Acute Myeloid Leukemia (AML)

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.